TRIP13 as a prognostic marker and its correlation with clinicopathological features in human cancers: a meta-analysis

Abstract

Background: Recent studies have shown thyroid hormone receptor interacting protein 13 (TRIP13) is involved in tumorigenesis and associated with poor clinical outcomes. Here, we conducted a meta-analysis to assess the effect of TRIP13 expression on clinicopathological features and prognosis in patients with different kinds of cancers. Methods: The comprehensive literature search was performed through the PubMed, Embase, and Web of Science electronic databases to identify eligible studies. The pooled hazard ratio (HR) and odds ratio (OR) with 95% confidence interval (CI) were calculated by STATA 15.0 software to evaluate the correlation between TRIP13 with overall survival (OS) and clinicopathology. Results: In total, 1461 patients from 12 studies were included in this meta-analysis. The pooled results suggested that high expression of TRIP13 correlated to unfavorable OS (HR=1.91, 95%CI 1.67-2.16, P<0.001) with no heterogeneity (I2=0.0, P=0.975). Subgroup analysis also indicated a significant association between high TRIP13 expression and poor OS regardless of tumor type, sample size, or method of data extraction. Moreover, a high level of TRIP13 was positively associated with tumor invasion depth (OR=2.86, 95%CI 1.38-5.94), lymph node metastasis (OR=3.72, 95%CI 2.65-5.20), distant metastasis (OR=2.64, 95%CI 1.42-4.91), and advanced TNM stage (OR=2.57, 95%CI 1.87-3.53) in patients with cancers. Conclusion: High expression of TRIP13 has a significant correlation with poor clinical outcomes and could serve as an unfavorable prognostic biomarker in cancer patients.